#United States #San Mateo #Kali Therapeutics #EHA 2026 #KT209

Kali Therapeutics Unveils KT209 at EHA 2026

Kali Therapeutics, a cutting-edge biotechnology firm based in San Mateo, California, has announced a significant milestone ahead of the European Hematology Association (EHA) 2026 Annual Congress. They will present groundbreaking preclinical data on their latest novel trispecific antibody, KT209. This presentation is slated for June 11-12, 2026, and will showcase how KT209 targets both CD19 and CD20, along with CD3, to effectively redirect T cells, achieving substantial depletion of B cells.

Overview of KT209

KT209 is not just another antibody. It is engineered to simultaneously engage CD19 and CD20 while co-targeting CD3 on T cells. This unique triple-targeting design aims to prevent the common problem of treatment failure seen with bispecific T-cell engagers (TCEs) that target single antigens, often due to the phenomenon known as antigen escape. By effectively targeting two antigens, KT209 demonstrates enhanced clinical outcomes and a powerful anti-tumor effect, complemented by a refined safety profile.

The upcoming poster presentation, titled “A Novel Trispecific Antibody KT209 Targeting CD19, CD20, and CD3 (CD19xCD20xCD3) Demonstrated Potent Activity in B-cell Diseases with Lower Cytokine Releases,” will be part of the first poster session, providing a deep dive into this innovative therapeutic agent.

Key Findings and Data Highlights

The preclinical data that Kali Therapeutics will present reflect a highly differentiated profile of KT209:

• - Resistance-Proof Cytotoxicity: KT209 has shown strong efficacy against Raji and Nalm19 leukemia cells. In particular, in Nalm19 models with low CD20 expression, the traditionally utilized TCE, glofitamab, experienced a marked drop in effectiveness, while KT209 maintained its robust tumor-killing capabilities.
• - Decoupling Potency from Toxicity: In assays using human peripheral blood mononuclear cells (PBMCs), KT209 exhibited a notable reduction in inflammatory cytokine release in comparison to glofitamab, addressing concerns related to Cytokine Release Syndrome (CRS).
• - In Vivo Tumor Clearance: The effectiveness of KT209 was also confirmed in humanized NOG mouse models, where it displayed potent, dose-dependent anti-leukemia action.
• - Favorable Safety in Non-Human Primates: A single subcutaneous dose of KT209 in non-human primates led to immediate and extensive B-cell depletion without any severe side effects, showcasing its potential for safe application in human clinical practice.

Insights from Leadership

John Wang, Chief Scientific Officer at Kali Therapeutics, shared insights into the impact of KT209, stating, “The data to be showcased at EHA underscores the highly differentiated profile of KT209. By integrating dual-antigen B-cell targeting with our proprietary CD3 masking technology, we have engineered a molecule that is fundamentally more potent than currently approved TCEs, particularly in low-antigen scenarios.”

Weihao Xu, CEO of Kali Therapeutics, further emphasized the strategic implications of this presentation, noting: “Our participation at EHA 2026 is a critical step in our ambition to expand into oncology. KT209 not only underscores our commitment to advancing therapies for hematologic malignancies but also reflects our ability to safely engage T cells in a versatile manner across various diseases.”

With clinical trials for KT209 anticipated to commence in early 2027, this trispecific antibody stands on the brink of potentially revolutionizing treatment protocols for serious B-cell diseases. As data continues to emerge, the scientific community anticipates a significant shift in how we approach therapies targeting these specific malignancies.

About Kali Therapeutics

Kali Therapeutics is dedicated to innovating therapeutic solutions through its proprietary methods in antibody engineering, aiming to drastically improve treatment pathways for individuals facing severe autoimmune disorders and advanced hematological cancers. The company is committed to pushing the boundaries of biopharmaceutical development, where technology meets life-saving therapies.